Santen Pharmaceutical Co., Ltd. (4536) Press Release
Summary of Consolidated Financial Results for the Three Months Ended June 30, 2026 (IFRS)
Earlier from Santen Pharmaceutical
- Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan
- Santen Pharmaceutical: China Signs Exclusive Distribution and Promotion Agreement for Five Marketed Glaucoma Eyedrops Products in the Chinese Mainland
- Santen Pharmaceutical: Notice of Board of Director and Corporate Auditor Nominations
- RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%